Isoprinosine and NPT 15392: immunomodulation and cancer.
These data demonstrate that both Isoprinosine and NPT 15392 are active nontoxic biological response modifiers that qualify for studies in cancer patients. Because of their immunomodulating properties, these agents are expected to be most appropriate in the treatment of immunosuppressed patients who are prone to infection or recurrence following cytoreductive therapy.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology*; D007109:Immunity / Q000187:drug effects; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000494:pharmacology*; D008214:Lymphocytes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D051381:Rats; D013045:Species Specificity
D000276:Adjuvants, Immunologic; D007042:Hypoxanthines; D007288:Inosine; C026533:NPT 15392; D007542:Inosine Pranobex